Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929027 | 1.00 | PDE4B (0.43) | PDE4BPDE4APDE4DHPGDCNR1 | |
| SCHEMBL13929009 | 0.91 | PDE4B (0.45) | PDE4BPDE4APDE4DHPGD | |
| SCHEMBL4187256 | 0.91 | PDE4B (0.45) | PDE4BPDE4APDE4DHPGD | |
| SCHEMBL4188763 | 0.90 | PDE4B (0.46) | PDE4BPDE4APDE4DCNR2 | |
| SCHEMBL13929026 | 0.90 | PDE4B (0.46) | PDE4BPDE4APDE4DCNR2 | |
| SCHEMBL5546898 | 0.89 | PDE4B (0.47) | PDE4BPDE4APDE4DHPGD | |
| SCHEMBL8302736 | 0.89 | PDE4B (0.43) | PDE4BPDE4APDE4DCNR1CNR2 | |
| SCHEMBL4193943 | 0.89 | PDE4B (0.43) | PDE4BPDE4APDE4DCNR1CNR2 | |
| SCHEMBL4186402 | 0.86 | MEN1 (0.46) | PDE4BPDE4APDE4DCNR1CNR2 | |
| SCHEMBL13929102 | 0.86 | MEN1 (0.46) | PDE4BPDE4APDE4DCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | claimed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | claimed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | PDE4B 719/4885PDE4A 1024/4885PDE4D 1102/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | PDE4B 719/4885PDE4A 1024/4885PDE4D 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.